4552 JCR Pharmaceuticals
- 660
- -3-0.45%
JCR Pharmaceuticals News
JCR Pharmaceuticals: Corporate Governance Report 2024/09/12
JCR Pharmaceuticals: JCR Pharmaceuticals’Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders
JCR Pharmaceuticals: Report on the presentation at SSIEM Annual Symposium 2024
JCR Pharmaceuticals: [Delayed]JCR Continues Support for Relay For Life Japan and Relay For Life of ASHIYA
JCR Pharmaceuticals: Announcement of sponsorship between Relay for Life Japan and Relay for Life Ashiya
JCR Pharmaceuticals: Acceptance of clinical trial plan notifications for the JR-441 phase I trial against mucopolysaccharidosis type IIIA and completion of the agency investigation regarding the clinical trial plan
JCR Pharmaceuticals: Acceptance of clinical trial plan notifications for the JR-441 phase I trial against mucopolysaccharidosis type IIIA and completion of the agency investigation regarding the clinical trial plan
JCR Pharmaceuticals: [Delay] Financial Summary Consolidated Performance for the 3 months ended June 30, 2024 (Fiscal Year 2024) (Japan GAAP)
JCR Pharmaceuticals: Announcements of individual stocks regarding the completion of payment for the disposal of treasury stock as stock compensation with transfer restrictions.
JCR Pharmaceuticals: Announcements of individual stocks regarding the completion of payment for the disposal of treasury stock as restricted stock compensation.
JCR Pharmaceuticals: Financial summary of the consolidated performance for the three months until June 30, 2024 (fiscal year 2024) (Japanese standard) (preliminary report).
JCR Pharmaceuticals: Earnings reports for Q1 of March 2025 will be announced in a conference call.
JCR Pharmaceuticals: 2024 Annual Q1 Earnings Conference Call
JCR Pharmaceuticals: Overview of Q1 2025 earnings report.
JCR Pharmaceuticals: 2025 March 1st quarter financial report announcement [Japan standard] (Consolidated)
JCR Pharmaceuticals: Announcements of individual stocks: Development of "Temcell HS injection" for neonatal hypoxic ischemic encephalopathy has been discontinued for expansion of indication (development code: JR-031HIE).
JCR Pharmaceuticals: JCR Pharmaceuticals has announced the discontinuation of TEMCELL HS Inj manufacture, expanding the indications for developing neonatal hypoxic-ischemic encephalopathy.
JCR Pharmaceuticals: Extraordinary Report
JCR Pharmaceuticals: Announcements of individual stocks regarding disposal of treasury stock as share-based compensation with transfer restrictions.
JCR Pharmaceuticals: Announcements of individual stocks regarding disposal of treasury stock as share-based compensation with transfer restrictions.
Analysis
Price Target
No Data
No Data